Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

References

• Torres J, Mehandru S, Colombel JF, et al. Crohn's disease. Lancet. 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Axelrad JE, Roy A, Lawlor G, et al. Thiopurines and inflammatory bowel disease: current evidence and a historical perspective. World J Gastroenterol. 2016;22:10103–10117.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862–869.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease—algorithm for practical management. Aliment Pharmacol Ther. 2016;43:30–51.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn's disease. Gastroenterology. 2018;155:1045–1058.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018;48:65–77.
   PubMed Web of Science ®Google Scholar
• European Commission Approves Stelara® [Ustekinumab] for treatment of adults with moderately to severely active Crohn’s disease. Beerse (Belgium): Johnson & Johnson Media Center; 2016.
   Google Scholar
• FDA Approves STELARA® [Ustekinumab] for treatment of moderate to severe Crohn’s disease. New York (NY): Crohn's & Colitis Foundation of America; 2016.
   Google Scholar
• Harris KA, Horst S, Gadani A, et al. Patients with refractory crohn's disease successfully treated with ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Ginard D, Marin-Jimenez I, et al. Ustekinumab for the treatment of refractory Crohn's disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018;47:588–595.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease—the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52:1354–1359.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn's disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242.e1-2–250.e1-2.
   Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn's disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23:833–839.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. J Crohns Colitis. [Epub ahead of print]
   Google Scholar
  .
   Google Scholar
• Summary of product characteristics, SmPC. Janssen Pharmaceutical Companies 2016. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf
   Google Scholar
• Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74–80.
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm Bowel Dis. 2006;12:304–310.
   PubMed Web of Science ®Google Scholar
• af Bjorkesten CG, Nieminen U, Turunen U, et al. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol. 2012;47:528–537.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.
   PubMed Web of Science ®Google Scholar
• Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2017;15:1427.e2–1434.e2.
   Web of Science ®Google Scholar
• Soufflet N, Boschetti G, Roblin X, et al. Concentrations of ustekinumab during induction therapy associate with remission in patients with Crohn's disease. Clin Gastroenterol Hepatol. [Epub ahead of print].
   Web of Science ®Google Scholar
• Papp K, Griffiths C, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–854.
   PubMed Web of Science ®Google Scholar
• Abedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease. Gastroenterology. 2018;154:1660–1671.
   PubMed Web of Science ®Google Scholar
• Gosh S, Kramer BC, Gasink C, et al. Long-term efficacy of ustekinumab with or without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years. J Crohn's Colitis. 2019;13:S459–S460.
   Google Scholar